Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

NeuroPace, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

NeuroPace, Inc.

Regulatory records
5
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 5 FDA records to the applicant name NeuroPace, Inc.. 2 entries are PMA supplements. 3 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Aug 18, 2025 to Aug 19, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code PFN appears in 5 of the 5 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P100026, with 5 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 455 N Bernardo Ave., Mountain View, CA, 94043. Recorded on P100026/S104, decision dated Aug 19, 2026.

Changes described in PMA records

P100026/S104: NeuroPace RNS System

FDA’s recorded scope: to remove an in-process screening test used in the manufacture of the RNS-320 Neurostimulators

Aug 19, 2026 · 30-Day Notice

P100026/S100: NeuroPace RNS System

FDA’s recorded scope: approval for migration of the Patient Data Management System from on-site server to cloud service

Jun 17, 2026 · Real-Time Process

P100026/S101: NeuroPace RNS System

FDA’s recorded scope: approval for an optional Electrocorticogram (ECoG) Assistant function, which is a clinician tool that highlights ECoG recordings of interest, for the Patient Data Management System.

May 28, 2026 · Normal 180 Day Track

P100026/S103: NeuroPace RNS System

FDA’s recorded scope: approval to change a supplier's ultrasonic rinse process for contacts used in the manufacture of the NeuroPace leads

Feb 20, 2026 · 30-Day Notice

P100026/S099: NeuroPace RNS System

FDA’s recorded scope: approval for the approved supplier of the RNS-320 Neurostimulator battery to procure a raw material from an alternate supplier

Aug 18, 2025 · 30-Day Notice

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
NeuroPace, Inc.PMA supplementAug 19, 2026FDA
NeuroPace, Inc.PMA supplementJun 17, 2026FDA
NeuroPace, Inc.PMA supplementMay 28, 2026FDA
NeuroPace, Inc.PMA supplementFeb 20, 2026FDA
NeuroPace, Inc.PMA supplementAug 18, 2025FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.